Major drug companies continually research and develop new medications and treatments, which must be shown to be safe and effective before doctors can prescribe them to patients. Through cervical cancerclinical trials, researchers test the effects of new drugs and treatments on a group of volunteers with cervical cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the treatments under development and measure the ability of the new drug or therapy to...
General Information About Gestational Trophoblastic Disease
This section was renamed from General Information About Gestational Trophoblastic Tumors and Neoplasia.
Revised text to state that gestational trophoblastic disease (GTD) is a broad term encompassing both benign and malignant growths arising from products of conception in the uterus.
Revised text to state that GTD may be classified as: hydatidiform mole (HM) including complete HM and partial HM; gestational trophoblastic neoplasia including Invasive mole, choriocarcinoma, and placental-site trophoblastic tumor; and, epithelioid trophoblastic tumor.
Cellular Classification of Gestational Trophoblastic Disease
This section was renamed from Cellular Classification of Gestational Trophoblastic Tumors and Neoplasia.
Revised text to state that gestational trophoblastic neoplasia is within the gestational trophoblastic disease classification.
Added text to state that choriocarcinoma, placental-site trophoblastic tumor and epithelioid trophoblastic tumor are often grouped under the heading gestational trophoblastic tumors.
Revised text to state that complete HMs have a 15% to 25% risk of developing into an invasive mole, but transformation to malignancy is much more rare in the case of partial moles.
Added text to state that invasive moles may be preceded by either complete or partial molar pregnancy.
Stage Information for Gestational Trophoblastic Disease
This section was renamed from Stage Information for Gestational Trophoblastic Tumors and Neoplasia.
Hydatidiform Mole (HM) Management
Revised text to state that chemotherapy is determined by the patient's modified World Health Organization score.
Recurrent or Chemoresistant Gestational Trophoblastic Neoplasia Treatment
This section was renamed from Recurrent or Chemoresistant Gestational Trophoblastic Tumor Treatment.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
In this article
This information is produced and provided by the National
Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National
Institute via the Internet web site at http://
.gov or call 1-800-4-CANCER.
WebMD Public Information from the National Cancer Institute
September 04, 2014
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this